glp 1 drugs for sleep apnea Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Syndrome Management: A Narrative Review Certain Patients Benefit Most from

but widespread use of these drugs is still relatively recent

About four in ten adults ages 50 to 64 and 65 and older say they have heard a lot about GLP-1 drugs, compared to about one-third of adults ages 30-49 (32%) and one in six adults ages 18-29 (17%)

Emerging dual agonists, such as tirzepatide (GLP-1/GIP) and pemvidutide or efinopegdutide (GLP-1/glucagon), have shown superior efficacy in promoting weight loss, improving hepatic and systemic inflammation, and enhancing cardiometabolic parameters

Waldrop G, Zhong J, Peters M, Rajagopalan S

As the effects of glucagon-like peptide 1 are glucose-dependent, the risk of hypoglycaemia with DPP4i is low

Lixisenatide: A New Option for Managing Type 2 Diabetes